Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer
NCT05863260 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2023-05-18
Summary
Tislelizumab combined with chemoradiotherapy in the treatment of recurrent/ metastasis cervical cancer: a single arm,single center， phase ii and observational clinical study
Conditions
- Cervical Cancer
- Immune Checkpoint Inhibitor
- Chemoradiotherapy
Interventions
- DRUG
-
Treatment Group
Treatment Group
Sponsors & Collaborators
-
Fudan University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-11-09
- Primary Completion
- 2023-12-31
- Completion
- 2024-12-31
Countries
- China
Study Locations
More Related Trials
-
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy
NCT04188860 ·Status: COMPLETED ·Phase: PHASE2
-
Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer
NCT06391190 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer
NCT06039891 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.
NCT06128460 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study
NCT04814069 ·Status: UNKNOWN ·Phase: PHASE2
-
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial
NCT05290935 ·Status: UNKNOWN ·Phase: PHASE2
-
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
NCT05311566 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
NCT06288360 ·Status: RECRUITING ·Phase: PHASE2
-
Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma
NCT05013268 ·Status: UNKNOWN ·Phase: PHASE1
-
Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
NCT05437692 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive
NCT03808857 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer
NCT02705612 ·Status: UNKNOWN ·Phase: PHASE2
-
Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC
NCT06878222 ·Status: RECRUITING ·Phase: PHASE2
-
Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 and IIA1 Cervical Cancer
NCT07130240 ·Status: RECRUITING ·Phase: PHASE2
-
A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients
NCT01755897 ·Status: COMPLETED ·Phase: NA
-
Study of Tumor Infiltrating Lymphocytes Following CCRT in the Treatment of Patients With Cervical Carcinoma
NCT04443296 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer
NCT05105672 ·Status: UNKNOWN ·Phase: PHASE2
-
RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer
NCT06063018 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Carilizumab Combined With Concurrent Chemoradiotherapy
NCT05151549 ·Status: UNKNOWN ·Phase: PHASE2
-
Adjuvant Chemotherapy and Anti-PD-1 Antibody in Patients With Stage IIIC2-IVB Cervical Cancer
NCT04918628 ·Status: UNKNOWN ·Phase: PHASE2
-
Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
NCT07167160 ·Status: RECRUITING ·Phase: PHASE2
-
Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors
NCT05824494 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer
NCT06998394 ·Status: RECRUITING ·Phase: PHASE2
-
Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer
NCT06511726 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
NCT05715840 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3